Core Viewpoint - Wei Jun Biotechnology (00660) reported a significant increase in revenue for the six months ending December 31, 2025, with a total revenue of HKD 352 million, representing a year-on-year increase of 118.65% [1] Financial Performance - The company recorded a loss attributable to shareholders of HKD 5.939 million, which is a reduction of 56.53% compared to the previous period [1] - Earnings per share for the period were HKD 0.0333 [1] Revenue and Profit Margins - The increase in revenue is attributed to a rise in market consumption and demand during the period [1] - Gross profit for the six months ending December 31, 2025, was approximately HKD 35.7 million, with a gross margin of 10.1% [1] - In comparison, for the six months ending December 31, 2024, the gross profit was about HKD 21.1 million, with a gross margin of approximately 13.1%, indicating an increase of about HKD 14.5 million but a decrease in margin by 3.0% [1]
玮俊生物科技发布中期业绩，股东应占亏损593.9万港元 同比减少56.53%